Marksans Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹11.41₹9.22₹8.40₹6.92₹6.41
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹11.41₹9.22₹8.40₹6.92₹6.41
₹66.71₹66.71₹54.44₹45.57₹38.51
₹69.99₹65.12₹57.88₹48.05₹40.87
—₹10.11₹4.56₹5.08₹5.24
₹7.23₹7.23₹0.74₹0.48₹4.06
—₹0.80₹0.65₹0.50₹0.22
45.345.34.545.345.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,290 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS6.416.928.409.2211.41
Diluted EPS6.416.928.409.2211.41
Book Value per Share38.5145.5754.4466.7166.71
Revenue per Share40.8748.0557.8865.1269.99
Cash Flow per Share5.245.084.5610.11—
Free Cash Flow per Share4.060.480.747.237.23
Dividends per Share0.220.500.650.80—
Shares Outstanding (cr)45.345.34.545.345.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.